Showing 3721-3730 of 8195 results for "".
- It's a Deal: Allergan Buys Luminera Dermal-Filler Businesshttps://practicaldermatology.com/news/its-a-deal-allergan-buys-luminera-dermal-filler-business/2460556/Allergan Aesthetics, an AbbVie company, has acquired Luminera's full dermal filler portfolio and R&D pipeline. Luminera is a privately held aesthetics company based in Israel with a portfolio and pipeline of dermal filler products. "
- Kubota Vision, LEO Pharma A/S to Screen Novel VAP-1 Inhibitors for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases/2460351/Kubota Vision Inc. signed an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis. During R&D activities to develop n
- Dr. Roy Geronemus Awarded the Inaugural Vic Narurkar, MD Innovations in Aesthetic Dermatology Lectureship Awardhttps://practicaldermatology.com/news/dr-roy-geronemus-awarded-the-vic-narurkar-md-innovations-in-aesthetic-dermatology-lectureship-award/2460210/Roy Geronemus, MD of Laser & Skin Surgery Center of New York received, The American Society for Dermatologic Surgery inaugural Vic Narurkar, M.D., Innovations in Aesthetic Dermatology Lectureship Award Dr. Geronemus received the award at the 2019 ASDS annual meeting in Chicago. He d
- LEO Pharma and Advancing Innovation in Dermatology Partner to Help Finance Accelerator Fundhttps://practicaldermatology.com/news/leo-pharma-and-advancing-innovation-in-dermatology-partner-to-help-finance-accelerator-fund/2457713/LEO Pharma and its Boston-based R&D innovation unit LEO Science & Tech Hub, and Advancing Innovation in Dermatology (AID) will each contribute $500,000 into the recently created Advancing Innovation in Dermatology Accelerator Fund. This non-profit fund is unique in its approach for suppor
- Dermatologist Publishes Practice Planning Guide, "Moxie Mindset"https://practicaldermatology.com/news/dermatologist-publishes-practice-planning-guide-moxie-mindset/2457804/New York City dermatologist Dina D. Strachan, MD has published "Moxie Mindset," a book that offers "secrets of building a profitable, independent physicians practice in a competitive environment." Dr. Strachan details her personal journey to building a thriv
- Estée Lauder Companies Anti-Aging Research On Skin Demonstrates Efficacy of Actives and Novel Technologies in Skin Researchhttps://practicaldermatology.com/news/este-lauder-companies-anti-aging-research-on-skin-demonstrates-efficacy-of-actives-and-novel-technologies-in-skin-research/2457874/The Estée Lauder Companies Research & Development (R&D) presented research focused on new findings in anti-aging skin research at the 2018 American Academy of Dermatology Annual Meeting in San Diego. The following reserach was presented at poster presentations at the AAD me
- High Doses of Sunshine Vitamin May Improve Sunburnhttps://practicaldermatology.com/news/high-doses-of-sunshine-vitamin-may-improve-sunburn/2458128/High doses of vitamin D taken one hour after sunburn may significantly reduce skin redness, swelling, and inflammation, according to double-blinded, placebo-controlled clinical trial out of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center.
- Anacor Submits NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitishttps://practicaldermatology.com/news/anacor-submits-nda-for-crisaborole-topical-ointment-2-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/2458765/Anacor Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the US FDA seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic d
- Rock Creek Pharmaceuticals Adds KOLs to Enhance Dermatological Disease Programhttps://practicaldermatology.com/news/rock-creek-pharmaceuticals-adds-kols-to-enhance-dermatological-disease-program/2458794/Rock Creek Pharmaceuticals, Inc., a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, has retained two Key Opinion Leaders (KOLs), each having renowned international expertise in dermatological d
- MEG 21 with Supplamine Now Available in Treatment Rooms with New Professional Size Dispensershttps://practicaldermatology.com/news/meg-21-with-supplamine-now-available-in-treatment-rooms-with-new-professional-size-dispensers/2458892/MEG 21 with Supplamine is a science-based company specializing in skin products for the face, neck, décolleté, and arms that uniquely remove toxic sugar from skin. Dynamis Skin Science, the parent company, was founded in 1997, based on the work of scientists initially working at Fox